Scarica l'app Stockscreener
2.065
0.72%
-0.015
Precedente Chiudi:
$2.08
Aprire:
$2.07
Volume 24 ore:
292.84K
Relative Volume:
0.03
Capitalizzazione di mercato:
$29.87M
Reddito:
$709.00K
Utile/perdita netta:
$-21.41M
Rapporto P/E:
-2.1737
EPS:
-0.95
Flusso di cassa netto:
$-19.70M
1 W Prestazione:
-0.24%
1M Prestazione:
-12.13%
6M Prestazione:
-54.11%
1 anno Prestazione:
-91.14%
Intervallo 1D:
$2.00
$2.10
Intervallo di 1 settimana:
$1.97
$2.135
Portata 52W:
$0.7707
$26.70
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Longeveron Inc Borsa (LGVN) Ultime notizie
Drug Maker Sued For Allegedly Concealing Drug’s Adverse Phase 2 Trial Results - Law360
Longeveron Inc [LGVN] Investment Guide: What You Need to Know - Knox Daily
Longeveron Inc (LGVN)’s stock price range in the last year - US Post News
Why has Longeveron stock tripled in two days? - MSN
Longeveron Inc’s Market Journey: Closing Weak at 1.97, Down -8.80 - The Dwinnex
LGVN’s Stock Market Adventure: -85.51% YTD Growth Amidst Volatility - The InvestChronicle
Insider Buying: Hare Joshua, Longeveron Inc [LGVN] Chief Scientific Officer invested 106,383 shares - Knox Daily
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.
Longeveron’s (LGVN) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on Longeveron stock, notes positive FDA alignment - Investing.com Canada
H.C. Wainwright maintains Buy on Longeveron stock, notes positive FDA alignment - Investing.com
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in - Daily Guardian Canada
Longeveron® Announces Positive Type C Meeting with U.S. FDA - GlobeNewswire
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS) - Yahoo Finance
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS) - StockTitan
Longeveron Inc’s latest rating changes from various analysts - Knox Daily
Ratio Analysis: Unpacking Longeveron Inc (LGVN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Longeveron Inc [NASDAQ: LGVN] Sees Decrease in Stock Value - Knox Daily
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference - MSN
Taking on analysts’ expectations and winning: Longeveron Inc (LGVN) - SETE News
Longeveron (NASDAQ:LGVN) Price Target Cut to $6.00 by Analysts at Maxim Group - Defense World
Beyond The Numbers: 4 Analysts Discuss Longeveron Stock - Benzinga
Reviewing MoonLake Immunotherapeutics (NASDAQ:MLTX) and Longeveron (NASDAQ:LGVN) - Defense World
Longeveron Inc (LGVN) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 - Marketscreener.com
LGVNLongeveron Inc. Latest Stock News & Market Updates - StockTitan
Longeveron Inc (LGVN) Becoming More Attractive for Investors - Knox Daily
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Is Longeveron Inc (LGVN) worth investing in despite its undervalued state? - US Post News
Daily Market Movement: Longeveron Inc (LGVN) Sees a -2.28 Decrease, Closing at 2.57 - The Dwinnex
Longeveron Inc (LGVN) Stock: A Year of Market Fluctuations - The InvestChronicle
A company insider recently bought 106,383 shares of Longeveron Inc [LGVN]. Should You Buy? - Knox Daily
Take off with Longeveron Inc (LGVN): Get ready for trading - SETE News
Can you now get a good deal on Longeveron Inc’s shares? - US Post News
A Guide To The Risks Of Investing In Longeveron Inc (LGVN) - Knox Daily
Ratios in Focus: Analyzing Longeveron Inc (LGVN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Longeveron Inc. Expected to Post Q3 2024 Earnings of ($0.51) Per Share (NASDAQ:LGVN) - Defense World
Longeveron (NASDAQ:LGVN) Stock Rating Reaffirmed by HC Wainwright - Defense World
Longeveron Inc (LGVN) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks - Investing.com India
Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks - Investing.com
Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks - Investing.com UK
Longeveron Inc. (NASDAQ:LGVN) Q2 2024 Earnings Call Transcript - Insider Monkey
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks - Investing.com Canada
LGVN Stock Earnings: Longeveron Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Healthy Upside Potential: Longeveron Inc (LGVN) - SETE News
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Longeveron Inc Azioni (LGVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hare Joshua | Chief Scientific Officer |
Apr 11 '24 |
Buy |
2.35 |
42,553 |
100,000 |
633,280 |
| Hashad Mohamed Wa'el Ahmed | Chief Executive Officer |
Apr 11 '24 |
Buy |
2.35 |
10,638 |
24,999 |
19,616 |
| Soffer Rock | Director |
Apr 10 '24 |
Buy |
2.35 |
106,383 |
250,000 |
176,619 |
| Soffer Rock | Director |
Apr 11 '24 |
Buy |
2.35 |
31,915 |
75,000 |
208,534 |
| Ross Cathy | Director |
Jan 10 '24 |
Buy |
1.31 |
5,000 |
6,544 |
10,000 |
| Baluch Khoso | Director |
Dec 29 '23 |
Buy |
1.43 |
8,322 |
11,915 |
15,000 |
| Baluch Khoso | Director |
Dec 28 '23 |
Buy |
1.40 |
1,678 |
2,342 |
6,678 |
| PFEFFER JEFFREY | Director |
Dec 28 '23 |
Buy |
1.35 |
10,000 |
13,500 |
15,000 |
| Hare Joshua | Chief Scientific Officer |
Sep 21 '23 |
Option Exercise |
3.00 |
5,000 |
15,000 |
7,828,263 |
| Lehr Paul T | General Counsel, Secretary |
Sep 20 '23 |
Option Exercise |
3.00 |
2,000 |
6,000 |
144,213 |
1.28%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):